Oxford Biomedica plc

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 05:42:26 2024-04-24 am EDT			5-day change	1st Jan Change
215.2 ^GBX	+0.12%		+14.76%	-0.68%

Apr. 18	Stifel Upgrades Oxford BioMedica to Buy from Hold, Lifts PT	MT
Apr. 18	HSBC likes Haleon, cuts Flutter to 'hold'	AN

Oxford Biomedica plc Announces Andrew Heath Will Not Be Standing for Re-Election at the 2021 AGM

April 15, 2021 at 02:00 am EDT

Oxford Biomedica plc announced that Dr. Andrew Heath will not be standing for re-election at the 2021 AGM having served on the Board since 2010.

Latest news about Oxford Biomedica plc

Stifel Upgrades Oxford BioMedica to Buy from Hold, Lifts PT	Apr. 18	MT
HSBC likes Haleon, cuts Flutter to 'hold'	Apr. 18	AN
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake	Mar. 20	AN
Oxford Biomedica Secures New Deal, Expands Existing Agreements for Clinical Programs	Mar. 20	MT
Oxford Biomedica plc Announces Board Changes	Mar. 11	CI
EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract	Mar. 05	AN
Oxford Biomedica plc Provides Earnings Guidance for the Year Ended December 31, 2023 and for the Fiscal Year 2024	Mar. 05	CI
Barclays cuts Bank of Ireland to 'equal weight'	Mar. 05	AN
EnSilica hires new chief financial officer from Oxford Biomedica	Feb. 05	AN
EnSilica Appoints Oxford Biomedica Executive as CFO	Feb. 05	MT
Oxford Biomedica Completes EUR15 Million ABL Europe Acquisition	Jan. 29	MT
Institut Merieux ups stake in Oxford BioMedica toward 10%	Jan. 29	AN
Oxford Biomedica plc completed the acquisition of additional 3.2% stake in ABL EUROPE S.A.S. from TSGH ?6.1 million	Jan. 28	CI
Transcript : Oxford Biomedica plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024	Jan. 09
Oxford BioMedica posts optimistic outlook on uptick in contract value	Dec. 07	AN
Oxford Biomedica plc Provides Business Update	Dec. 07	CI
Goldman lifts Landsec and British Land	Dec. 05	AN
Oxford Biomedica to Buy ABL Europe from Institut Mérieux	Dec. 04	MT
Oxford BioMedica buys ABL Europe for consideration of EUR15 million	Dec. 04	AN
Oxford Biomedica plc entered into a sale and purchase agreement to acquire additional 3.2% stake in ABL EUROPE S.A.S. from TSGH.	Dec. 03	CI
Oxford Biomedica plc entered into a sale and purchase agreement to acquire ABL EUROPE S.A.S. from TSGH for ?15 million.	Dec. 03	CI
Record down as managed assets decline	23-10-20	AN
Citigroup cuts Wizz Air to 'sell'	23-10-18	AN
Transcript : Oxford Biomedica plc - Special Call	23-10-02
BoA likes Dowlais; JPMorgan cuts Phoenix Group	23-09-22	AN

Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.

Sector

Biotechnology & Medical Research

Calendar

2024-04-29 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Oxford Biomedica plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.15 GBP

Average target price

3.963 GBP

Spread / Average Target

+84.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OXFORD BIOMEDICA PLC	-0.68%	267M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+3.44%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-7.33%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs